

# Narcolepsy

[View the current Narcolepsy InDepth page on BioPortfolio.com \(PDF\)](#)

(<http://www.bioportfolio.com/indepth/Narcolepsy.html>) - Regularly Updated.

Narcolepsy is a neurological condition most characterized by Excessive Daytime Sleepiness . A narcoleptic will most likely experience disturbed nocturnal sleep, which is often confused with insomnia, and disorder of REM or rapid eye movement sleep. It is one of the dyssomnias. A narcoleptic may also sleep at any random time. The term narcolepsy derives from the French word narcolepsie created in 1880 by the French physician Jean-Baptiste-Ã‰douard GÃ©lineau by combining the Greek narke numbness, stupor and lepsia attack, seizure. ([From the Wikipedia article Narcolepsy](#).)



## Recent Publications on Narcolepsy:

- [Polymorphism located in TCRA locus confers susceptibility to essential hypersomnia with HLA-DRB1\\*1501-DQB1\\*0602 haplotype.](#)  
*Essential hypersomnia (EHS) exhibits excessive daytime sleepiness without...* 21st November, 2009  
Department of Human Genetics, Graduate School of Medicine, The University- J Hum Genet. 2009 Nov 20. ([DOI Direct Link](#))
- [Orexin/Hypocretin and Histamine: Distinct Roles in the Control of Wakefulness Demonstrated Using Knock-Out Mouse Models.](#)  
*To determine the respective role played by orexin/hypocretin and histamine...* 20th November, 2009  
Inserm-U628, Integrated Physiology of Brain Arousal Systems, IFR19, 69373- J Neurosci. 2009 Nov 18;29(46):14423-14438. ([DOI Direct Link](#))
- [Orexins Excite Neurons of the Rat Cerebellar Nucleus Interpositus Via Orexin 2 Receptors In Vitro.](#)  
*Orexins are newfound hypothalamic neuropeptides implicated in the...* 19th November, 2009  
Department of Biological Science and Technology and State Key Laboratory- Cerebellum. 2009 Nov 19. ([DOI Direct Link](#))
- [Modafinil in the treatment of excessive sleepiness.](#)  
*The wake-promoting agent modafinil is approved for the treatment of...* 19th November, 2009  
INTEGRIS Sleep Disorders Center and University of Oklahoma Health Sciences- Drug Des Devel Ther. 2009 Feb 6;2:71-85.
- [Hypocretin measurement in an icelandic foal with narcolepsy.](#)  
*The wake-promoting agent modafinil is approved for the treatment of...* 17th November, 2009  
Department of Small Animal Medicine and Surgery, University of Veterinary- J Vet Intern Med. 2009 Nov-Dec;23(6):1299-302. ([DOI Direct Link](#))
- [Narcolepsy presenting as refractory epilepsy.](#)  
*The wake-promoting agent modafinil is approved for the treatment of...* 13th November, 2009  
- Indian J Pediatr. 2009 Oct;76(10):1073. ([DOI Direct Link](#))
- [Phospholipase C-beta4 is essential for the progression of the normal sleep sequence and ultradian](#)

[body temperature rhythms in mice.](#)

*BACKGROUND: THE SLEEP SEQUENCE: i) non-REM sleep, ii) REM sleep, and iii)...*10th November, 2009

Department of Chronobiology, Graduate School of Innovative Life Science,- PLoS One. 2009 Nov 9;4(11):e7737. ([DOI Direct Link](#))

- [A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing.](#)  
*OBJECTIVE: Sodium oxybate (SXB) is an approved drug for the treatment of...*10th November, 2009  
University of Western Ontario, London Health Sciences Centre, 375 South- Sleep Med. 2009 Nov 6. ([DOI Direct Link](#))
- [REM-dreams recall in patients with narcolepsy-cataplexy.](#)  
*An abundant recall of dreams has been observed in clinical studies on...*10th November, 2009  
Department of Psychology, University of Bologna, Viale Berti Pichat 5,- Brain Res Bull. 2009 Nov 6. ([DOI Direct Link](#))
- [\[Narcolepsy with and without cataplexy: An uncommon disabling and unrecognized disease.\]](#)  
*Although narcolepsy is a relatively uncommon condition, its impact on a...*7th November, 2009  
Unidad Pediatrica de Trastornos de Sueno, Hospital Universitario La Paz,- An Pediatr (Barc). 2009 Dec;71(6):524-534. Epub 2009 Nov 5. ([DOI Direct Link](#))
- [Chapter 8 The development of neurology and the neurological sciences in the 17th century.](#)  
*Circa 1660 several favorable factors, instrumental to the invention of...*7th November, 2009  
- Handb Clin Neurol. 2009;95:91-106. ([DOI Direct Link](#))
- [Gray matter concentration abnormality in brains of narcolepsy patients.](#)  
*OBJECTIVE: To investigate gray matter concentration changes in the brains...*4th November, 2009  
Department of Neurology, Sleep Center, Samsung Medical Center,- Korean J Radiol. 2009 Nov-Dec;10(6):552-8. ([DOI Direct Link](#))
- [Sleep disorders in patients with multiple sclerosis.](#)  
*Patients with multiple sclerosis (MS) often have unrecognized sleep...*3rd November, 2009  
Co-Director of Sleep Medicine, Department of Neurology, UC Davis School of- Sleep Med Rev. 2009 Oct 28. ([DOI Direct Link](#))
- [The genetics of sleep disorders in humans: narcolepsy, restless legs syndrome, and obstructive sleep apnea syndrome.](#)  
*Sleep disorders are a group of neurological disorders known to cause...*31st October, 2009  
Department of Biochemistry and Clinical Biochemistry, Firat University,- Am J Med Genet A. 2009 Nov;149A(11):2612-26. ([DOI Direct Link](#))
- [A brain PET study in patients with narcolepsy-cataplexy.](#)  
*OBJECTIVE: To investigate brain changes in both basal and cataplectic...*24th October, 2009  
Service de Neurologie, Unite des Troubles du Sommeil, CHU Montpellier,- J Neurol Neurosurg Psychiatry. 2009 Oct 22. ([DOI Direct Link](#))

## BioNews Results for Narcolepsy

- [Hypersomnia](#)  
*KIMT.COM: Nov 16 2009 8:51AM Matching: narcolepsy*
- [Stakeholder Opinions - Narcolepsy - Entry-point to a lucrative fatigue-associated market - research report rel](#)  
*PR inside: Oct 23 2009 8:44PM Matching: narcolepsy*





## Narcolepsy Patents:

- 7569602- [Furan derivatives as EP.sub.4 receptor antagonists](#)
- 7579380- [Modified release formulations of a bupropion salt](#)
- 7579474- [Substituted piperidines as modulators of dopamine neurotransmission](#)
- 7585897- [Modified release formulations of a bupropion salt](#)
- 7589066- [Potent and specific immunoproteasome inhibitors](#)
- 7589093- [Alkyl substituted indoloquinolines](#)
- 7589096- [Azole derivatives](#)
- 7589097- [Triazol\[4,5-d\] pyrimidine derivatives and their use as purinergic receptor antagonists](#)
- 7589206- [Pyrrolopyridine derivatives](#)
- 7592010- [Albumin fusion proteins](#)
- 7592333- [Lorazepam analogs and methods of use thereof](#)
- 7579362- [Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists](#)
- 7579351- [Tricyclic amide derivatives](#)
- 7576133- [Methods and compositions for nasal administration of modafinil](#)
- 7569610- [Modified release formulations of a bupropion salt](#)
- 7569611- [Modified release formulations of a bupropion salt](#)
- 7572605- [Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers](#)
- 7572776- [N-\(phosphonoalkyl\)-amino acids, derivatives thereof and compositions and methods of use](#)
- 7572786- [Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists](#)
- 7572792- [Azetidine glycine transporter inhibitors](#)
- 7572819- [Compounds which potentiate glutamate receptor and uses thereof in medicine](#)
- 7572935- [Modified release formulations of a bupropion salt](#)
- 7576083- [Morpholinyl piperidine glycine transporter inhibitors](#)
- 7576110- [Benzothiazole cyclobutyl amine derivatives](#)
- 7592346- [Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors](#)
- 7592347- [Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases](#)
- 7612056- [Substituted diaza-spiro-\[4.5\]-decane derivatives and their use as neurokinin antagonists](#)
- 7612074- [Diazabicyclic aryl derivatives as cholinergic ligands](#)
- 7612076- [Piperazinyl-pyridine derivatives](#)
- 7612090- [Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof](#)
- 7615550- [Substituted piperazines, \(1,4\) diazepines, and 2,5-diazabicyclo \(2.2.1\)heptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists](#)
- 7615648- [Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake](#)
- 7618650- [Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof](#)
- 7618786- [Method for identifying modulators of human orexin-2 receptor](#)
- 7618969- [Compounds which potentiate glutamate receptor and uses thereof in medicine](#)
- 7619005- [Methods for treating cognitive impairment in humans with Multiple Sclerosis](#)
- 7611858- [Detection of cannabinoid receptor biomarkers and uses thereof](#)
- 7610083- [Method and system for loop recording with overlapping events](#)
- 7608617- [Naphthalene derivatives as H3 inverse agonists](#)
- 7593767- [Ambulatory sleepiness and apnea propensity evaluation system](#)
- 7595315- [Morpholine derivatives as norepinephrine reuptake inhibitors](#)

- 7595316- [Heteroaryloxy nitrogenous saturated heterocyclic derivative](#)
- 7598048- [Screening methods for identifying agents that modulate output of a circadian pacemaker](#)
- 7598256- [Pyrrolo \[2,3-d\] pyrimidine and their use as purinergic receptor antagonists](#)
- 7598423- [Potentiators of glutamate receptors](#)
- 7601335- [Pretreatment of a biological sample from an autoimmune disease subject](#)
- 7601711- [5-amido-indole-2-carboxamide derivatives](#)
- 7601740- [Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases](#)
- 7601744- [Benzothiadiazolyphenylalkylamine derivatives and methods of their use](#)
- 7619096- [3-Aminopyrrolidines as inhibitors of monoamine uptake](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

